453 related articles for article (PubMed ID: 24501221)
21. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
[TBL] [Abstract][Full Text] [Related]
22. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
23. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
24. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.
Amin NA; Seymour E; Saiya-Cork K; Parkin B; Shedden K; Malek SN
Clin Cancer Res; 2016 Sep; 22(17):4525-35. PubMed ID: 27060156
[TBL] [Abstract][Full Text] [Related]
25. An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.
Worrillow L; Baskaran P; Care MA; Varghese A; Munir T; Evans PA; O'Connor SJ; Rawstron A; Hazelwood L; Tooze RM; Hillmen P; Newton DJ
Oncogene; 2016 Oct; 35(40):5328-5336. PubMed ID: 27041575
[TBL] [Abstract][Full Text] [Related]
26. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
29. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
Lazarian G; Tausch E; Eclache V; Sebaa A; Bianchi V; Letestu R; Collon JF; Lefebvre V; Gardano L; Varin-Blank N; Soussi T; Stilgenbauer S; Cymbalista F; Baran-Marszak F
Int J Cancer; 2016 Oct; 139(8):1759-63. PubMed ID: 27270786
[TBL] [Abstract][Full Text] [Related]
30. Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
László T; Kotmayer L; Fésüs V; Hegyi L; Gróf S; Nagy Á; Kajtár B; Balogh A; Weisinger J; Masszi T; Nagy Z; Farkas P; Demeter J; Istenes I; Szász R; Gergely L; Sulák A; Borbényi Z; Lévai D; Schneider T; Pettendi P; Bodai E; Szerafin L; Rejtő L; Bátai Á; Dömötör MÁ; Sánta H; Plander M; Szendrei T; Hamed A; Lázár Z; Pauker Z; Radványi G; Kiss A; Körösmezey G; Jakucs J; Dombi PJ; Simon Z; Klucsik Z; Gurzó M; Tiboly M; Vidra T; Ilonczai P; Bors A; Andrikovics H; Egyed M; Székely T; Masszi A; Alpár D; Matolcsy A; Bödör C
J Pathol Clin Res; 2024 Jan; 10(1):e351. PubMed ID: 37987115
[TBL] [Abstract][Full Text] [Related]
31. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Malcikova J; Pavlova S; Kunt Vonkova B; Radova L; Plevova K; Kotaskova J; Pal K; Dvorackova B; Zenatova M; Hynst J; Ondrouskova E; Panovska A; Brychtova Y; Zavacka K; Tichy B; Tom N; Mayer J; Doubek M; Pospisilova S
Blood; 2021 Dec; 138(25):2670-2685. PubMed ID: 33945616
[TBL] [Abstract][Full Text] [Related]
32. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
33. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
34. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
Liu YC; Margolskee E; Allan JN; Mathew S; Bhavsar E; Casano J; Orazi A; Furman RR; Geyer JT
Mod Pathol; 2020 Mar; 33(3):344-353. PubMed ID: 31477813
[TBL] [Abstract][Full Text] [Related]
35. The clinical implications of gene mutations in chronic lymphocytic leukaemia.
Rossi D; Gaidano G
Br J Cancer; 2016 Apr; 114(8):849-54. PubMed ID: 27031852
[TBL] [Abstract][Full Text] [Related]
36.
Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
[TBL] [Abstract][Full Text] [Related]
37. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
38. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
39. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.
Jethwa A; Hüllein J; Stolz T; Blume C; Sellner L; Jauch A; Sill M; Kater AP; te Raa GD; Geisler C; van Oers M; Dietrich S; Dreger P; Ho AD; Paruzynski A; Schmidt M; von Kalle C; Glimm H; Zenz T
Br J Haematol; 2013 Nov; 163(4):496-500. PubMed ID: 24032483
[TBL] [Abstract][Full Text] [Related]
40. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
